Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sigyn Therapeutics Inc (QB) | SIGYD | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.75 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.75 | 4.75 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 3.00 - 6.00 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 4.75 | USD |
Sigyn Therapeutics Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 210.07M | 44.22M | 8.63M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Sigyn Therapeutics (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/06/2024 | 15:37 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/15/2024 | 16:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 4/16/2024 | 16:17 | Edgar (US Regulatory) | Form 8-K - Current report |
| 4/10/2024 | 16:28 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities.. |
| 2/20/2024 | 15:55 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SIGYD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 3.00 | 6.00 | 3.00 | 4.97 | 310 | 1.75 | 58.33% |
| 1 Year | 3.00 | 6.00 | 3.00 | 4.97 | 310 | 1.75 | 58.33% |
| 3 Years | 3.00 | 6.00 | 3.00 | 4.97 | 310 | 1.75 | 58.33% |
| 5 Years | 3.00 | 6.00 | 3.00 | 4.97 | 310 | 1.75 | 58.33% |
Sigyn Therapeutics (QB) Description
| Sigyn Therapeutics is a development-stage company focused on creating therapeutic solutions to address unmet needs in global health. Sigyn Therapy, the Companys lead product candidate, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders that are not addressed with approved drug therapies. Candidate treatment indications for Sigyn Therapy include chronic inflammation and endotoxemia in end-stage renal disease patients, sepsis (leading cause of hospital deaths), community acquired pneumonia (a leading cause of death among infectious diseases), and emerging pandemic threats. The Company's development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the delivery of FDA approved chemotherapeutic agents and ChemoPure to reduce chemotherapy toxicity. |
